Franck Morschhauser

Franck Morschhauser

UNVERIFIED PROFILE

Are you Franck Morschhauser?   Register this Author

Register author
Franck Morschhauser

Franck Morschhauser

Publications by authors named "Franck Morschhauser"

Are you Franck Morschhauser?   Register this Author

100Publications

4719Reads

43Profile Views

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

N Engl J Med 2018 09;379(10):934-947

From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d'Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and Département d'Hématologie, Université de Rouen, Rouen (H.T.), Institut d'Hématologie de Basse Normandie, Caen (C.F.), CHU Le Bocage Service d'Hématologie Clinique, Dijon (R.-O.C.), Hôpital Henri Mondor Unité Hémopathies Lymphoïdes, Créteil (C.H.), Centre Hospitalier Départemental Vendée Service d'Onco-Hématologie, La Roche sur Yon (H.M.), Institut Universitaire du Cancer de Toulouse Oncopole Service d'Hématologie, Toulouse (L.Y.), CHU Bordeaux, Service d'Hématologie, Bordeaux (K.B.), Hôpital Saint Louis Service d'Onco-Hématologie, Paris (P.B.), Gustave Roussy Cancer, Villejuif (V.R.), Centre Hospitalier Annecy Genevois Service, Annecy (N.D.), CHU de Nantes-Hôtel Dieu Service d'Hématologie Clinique, Centre de Recherche en Cancerologie et Immunologie, INSERM, Centre National de la Recherche Scientifique, Université de Nantes, Nantes (S.L.G.), Centre Hospitalier Métropole Savoie Service Hématologie, Chambery (G.M.P.), Department of Hematology, CHU Montpellier, University of Montpellier, Montpellier (G.C.), and Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, University of Lyon, Pierre-Benite (G.A.S.) - all in France; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (N.H.F.); the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (M.L.P.); the Department of Medicine, Division of Medical Oncology, University of Washington, Seattle (E.N.L.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.W.F.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (N.L.B.); the Department of Hematology, Hospital Universitario de Salamanca and Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Salamanca (A.M.G.-S.), and the Department of Hematology, Hospital Clinic de Barcelona, Barcelona (A.L.-G.) - both in Spain; CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec (J.-F.L.), and British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia, Vancouver (L.H.S.) - both in Canada; the Department of Hematology and Oncology, Tokai University Hospital, Kanagawa, Japan (K.A.); Instituto Português de Oncologia Lisboa Francisco Gentil Departamento de Hematologia, Lisbon (M.G.S.); the Department of Hematology, CHU Université Catholique de Louvain Namur, Yvoir (M.A.), and the Department of Hematology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp (P.Z.) - both in Belgium; the Department of Hematology, National Cancer Center Hospital, Tokyo, Japan (K.T.); and Celgene, Summit, NJ (D.L., J.W.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805104
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805104DOI Listing
September 2018

Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controls.

Reprod Biomed Online 2018 May 19;36(5):543-551. Epub 2018 Feb 19.

Institut de Biologie de la Reproduction-Spermiologie-CECOS, hôpital Jeanne de Flandre, Centre Hospitalier Universitaire de Lille, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rbmo.2018.01.016DOI Listing
May 2018

Through the Glass Ceiling.

J Clin Oncol 2018 03 25;36(9):923. Epub 2018 Jan 25.

Hervé Tilly, Centre Henri Becquerel, Université de Rouen, Institut National de la Santé et de la Recherche Médicale 1245, Rouen, France; Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon-1, Institut National de la Santé et de la Recherche Médicale 1052, Pierre-Bénite, France; Thierry J. Molina, Assistance Publique-Hôpitaux de Paris, Necker, Université Paris Descartes, Paris, France; René-Olivier Casasnovas, Hôpital Le Bocage, Dijon, France; Franck Morschhauser, Université de Lille, Centre Hospitalier Universitaire Lille and Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France; and Bertrand Coiffier, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon-1, Institut National de la Santé et de la Recherche Médicale 1052, Pierre-Bénite, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.3961DOI Listing
March 2018

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

J Clin Oncol 2017 Dec 4;35(35):3898-3905. Epub 2017 Oct 4.

Martin Dreyling, Ludwig Maximilians University of Munich, Munich; Georg Lenz, University Hospital Münster, Münster; Marius Giurescu, Karl Köchert, Henrik Seidel, and Florian Hiemeyer, Bayer AG, Berlin, Germany; Armando Santoro, Humanitas Clinical and Research Center, Rozzano; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; Luigina Mollica, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; George A. Follows, Addenbrooke's Hospital, Cambridge, United Kingdom; Won Seog Kim, Samsung Medical Center, Seoul, South Korea; Arnon Nagler, Tel Aviv University, Tel HaShomer, Israel; Panayiotis Panayiotidis, National and Kapodistrian University of Athens, Athens, Greece; Judit Demeter, Semmelweis University, Budapest, Hungary; Muhit Özcan, Ankara University School of Medicine, Ankara, Turkey; Marina Kosinova, Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation; Krimo Bouabdallah, University Hospital of Bordeaux, Pessac; Franck Morschhauser, Hôpital Claude Huriez, Lille, France; Don A. Stevens, Norton Cancer Institute, Louisville, KY; David Trevarthen, Comprehensive Cancer Care and Research Institute of Colorado, Englewood, CO; and Lisa Cupit, Li Liu, Carol Peña, Shuxin Yin, Jose Garcia-Vargas, and Barrett H. Childs, Bayer HealthCare Pharmaceuticals, Whippany, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.4648DOI Listing
December 2017

[Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Bull Cancer 2017 Dec 22;104(12S):S131-S135. Epub 2017 Nov 22.

Universitätsklinikum Aachen, Klinik für Onkologie, Hämatologie und Stammzelltransplantation, Aachen, Allemagne; Institut de cancérologie Lucien-Neuwirth, département d'hématologie clinique, Saint-Priest-en-Jarez, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2017.10.018DOI Listing
December 2017

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

N Engl J Med 2017 09;377(13):1250-1260

From Service d'Hématologie Clinique (S.L.G., T.G.), Service d'Anatomopathologie (A.M.), and Service d'Hématologie Biologique (M.C.B.), Hôtel-Dieu Centre Hospitalier Universitaire (CHU) de Nantes, and Centre de Recherche en Cancérologie et Immunologie (S.L.G., M.C.B.) and Faculté de Médecine (S.L.G.), Université de Nantes, Nantes, Hemato-Oncologie, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Université Diderot Sorbonne Paris-Cité (C.T.), Université Descartes (C.T.), Département d'Hématologie, Faculté de Médecine, Université Paris-Sud (V.R.), Département d'Anatomopathologie (D.C.) and Département d'Hématologie (O.H.), Necker Hospital, APHP, Sorbonne Paris-Cité, and INSERM Unité 1163 et Centre National de la Recherche Scientifique (CNRS) Équipe de Recherche Labellisée 8654, Imagine Institute (O.H.), Paris, Département d'Hématologie, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse (L.O.), Service d'Hématologie Clinique et Thérapie Cellulaire, CHU de Bordeaux, Bordeaux (K.B.), Service d'Hématologie et Thérapie Cellulaire, CHU de Tours, Tours (C.D.), Service d'Hématologie, CHU d'Amiens, Amiens (G.D.), INSERM, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif (V.R.), Département d'Hématologie, CHU de Nancy, Nancy (P.F.), INSERM Unité 954, Vandoeuvre (P.F.), Service d'Hématologie Clinique, CHU de Dijon, and INSERM Unité Mixte de Recherche 1231, Dijon (O.C.), Service d'Hématologie, Centre Hospitalier d'Avignon, Avignon (H.Z.), Lymphoid Malignancies Unit, Hôpital Henri Mondor, APHP, Créteil (C.H.), Service d'Hématologie du Centre Hospitalier de Vendée, La Roche-sur-Yon (H.M.), Service Hématologie Clinique (R.H.) and Département d'Hématologie (T.L.), CHU de Rennes, INSERM Unité 917 (R.H.), and INSERM Unité 1236 (T.L.), Rennes, Département d'Hematology, Centre Henri-Becquerel et Université de Normandie Unité 1245, Rouen (F.J., H.T.), Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, CHU de Clermont-Ferrand et Université Clermont Auvergne, Clermont-Ferrand (O.T.), Service d'Hématologie, Clinique Victor Hugo, Le Mans (K.L.D.), Department of Hematology, Université de Lille, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, and CHU de Lille, Lille (F.M.), Département d'Hématologie Clinique, CHU de Montpellier, CNRS UMR 5235, Montpellier (G.C.), Service d'Oncologie et d'Hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg (L.-M.F.), INSERM 1209, CNRS UMR 5309, Faculté de Médecine, Université Grenoble Alpes (M.C., R.G.), Institute for Advanced Biosciences (M.C.), and Laboratoire de Génétique Onco-hématologie (M.C.) and Faculté de Médecine (R.G.), CHU de Grenoble Alpes, Grenoble, Service d'Hématologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite (G.S.), and Université Claude Bernard Lyon 1 and Cancer Research Center of Lyon, INSERM 1052 CNRS 5286 Lyon, Lyon (G.S.) - all in France; and Département d'Hématologie, Cliniques Universitaires Saint-Luc-Université Catholique de Louvain, Brussels (E.V.D.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1701769DOI Listing
September 2017

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

J Clin Oncol 2017 Aug 20;35(22):2473-2481. Epub 2017 Apr 20.

Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.6984DOI Listing
August 2017

The landscape of new drugs in lymphoma.

Nat Rev Clin Oncol 2017 Jun 29;14(6):335-346. Epub 2016 Dec 29.

UNMC Oncology/Haematology Division, 987680 Nebraska Medical Center, Omaha, Nebraska 681980-7680, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5611863PMC
June 2017

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

J Clin Oncol 2017 Jun 29;35(17):1905-1912. Epub 2017 Mar 29.

Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.6994DOI Listing
June 2017

Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.

J Clin Oncol 2017 Feb 19;35(5):536-543. Epub 2016 Dec 19.

Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.3564DOI Listing
February 2017

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.

J Clin Oncol 2017 Feb 28;35(5):552-560. Epub 2016 Dec 28.

Qian Shi and Daniel J. Sargent, Mayo Clinic, Rochester; Bruce A. Peterson, University of Minnesota, Minneapolis, MN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Wolfgang Hiddemann and Eva Hoster, Ludwig-Maximilians University Hospital, Munich; Michael Herold, HELIOS Kliniken, Erfurt, Germany; Robert Marcus, Addenbrooke's Hospital, Cambridge, United Kingdom; Anton Hagenbeek, Academic Medical Center, Amsterdam, the Netherlands; Eva Kimby, Karolinska Institutet, Stockholm, Sweden; Howard Hochster, Yale Cancer Center, New Haven, CT; Umberto Vitolo, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin; Marco Ladetto, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; Emmanuel Gyan, University Hospital, Tours; Franck Morschhauser, Service Université de Lille 2, Lille; Gilles Salles, Université Claude Bernard, Pierre Bénite, France; Michele Ghielmini and Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona; Michele Ghielmini and Emanuele Zucca, Swiss Group for Clinical Cancer Research, Bern; Tina Nielsen, F. Hoffmann-La Roche, Basel; Sabine De Bedout, Celgene, Boudry, Switzerland; Tommy Fu, Celgene, Summit, NJ; Nancy Valente, Genentech, South San Francisco, CA; and Nathan H. Fowler, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.8651DOI Listing
February 2017

Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation.

Leuk Lymphoma 2017 01 17;58(1):222-225. Epub 2016 May 17.

a Department of Internal Medicine I, German Hodgkin Study Group (GHSG) , University Hospital of Cologne , Kerpener Str. 62 , Cologne , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1182164DOI Listing
January 2017

Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.

Neurology 2017 01 18;88(1):101-102. Epub 2016 Nov 18.

From the French LOC Network for PCNSL, Hôpital René Huguenin-Institut Curie (K.C., C.S.), Saint-Cloud; French LOC Network for PCNSL, GH Pitié-Salpêtrière (S.C., C.H., K.H.-X.), Paris; French LOC Network for PCNSL, CHU Lille (E.B., F.M.); French LOC Network for PCNSL, CH Potiers (D.L.-C., V.D.); French LOC Network for PCNSL, CH Argenteuil (A.A.J.), France; and Université Libre de Belgiques (V.D.), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000003420DOI Listing
January 2017

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Neuro Oncol 2016 09 6;18(9):1297-303. Epub 2016 Mar 6.

Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article-lookup/doi/1
Publisher Site
http://dx.doi.org/10.1093/neuonc/now033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998995PMC
September 2016

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.

Haematologica 2016 Feb 11;101(2):226-34. Epub 2015 Dec 11.

Roche Pharmaceutical Research and Early Development, Roche Innovation Center Welwyn, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.133421DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938339PMC
February 2016

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.

J Clin Oncol 2015 Sep 20;33(25):2803-11. Epub 2015 Jul 20.

John G. Gribben, Barts Cancer Institute, London, United Kingdom; Nathan Fowler, The University of Texas MD Anderson Cancer Center, Houston, TX; and Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Unité Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.5363DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320950PMC
September 2015

Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.

Invest New Drugs 2015 Apr 21;33(2):423-31. Epub 2015 Jan 21.

Centre Hospitalier Régional de Lille, Hôpital Claude Huriez, Service des maladies du sang, Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA), Université de Lille, Lille, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0206-xDOI Listing
April 2015

Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.

Expert Opin Drug Saf 2015 Apr 25;14(4):601-7. Epub 2015 Feb 25.

Hôpital Claude Huriez, Service des maladies du sang , CHRU Lille, 59000 , France +0033 320 44 42 92 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2015.1010505DOI Listing
April 2015

Bendamustine is effective in T-cell prolymphocytic leukaemia.

Br J Haematol 2015 Mar 15;168(6):916-9. Epub 2014 Oct 15.

Service des Maladies du Sang, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13175DOI Listing
March 2015

MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.

Br J Haematol 2014 Nov 27;167(4):506-13. Epub 2014 Aug 27.

Service d'Hématologie-Immunologie -Cytogénétique, Centre Hospitalier de Valenciennes, Valenciennes, France; Laboratoire d'Hématologie, Centre de Biologie Pathologie, CHRU, Lille, France; U837, IRCL, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13078DOI Listing
November 2014

Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.

Cancer Treat Rev 2014 Oct 24;40(9):1080-8. Epub 2014 Aug 24.

Institute of Hematology "Seràgnoli", University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.08.001DOI Listing
October 2014

The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.

Medicine (Baltimore) 2014 Oct;93(17):255-66

Institut d'Immunologie, Réseau Eosinophile, EA2686 (GL, FL, DL, ML, JT, JEK), Service d'Immunologie Clinique et de Médecine Interne, Centre de Référence Maladies Auto-Immunes Systémiques (GL, DL, LT, NLG, PYH), Institut de Pathologie (MCC), Service de Dermatologie (DSS), Service des Maladies du Sang (FM), Institut de Génétique Médicale, U837 Inserm (CRL), Réseau Eosinophile, U995 Inserm (MC), CHRU de Lille, Université Lille Nord de France, Lille; Service de Dermatologie (MAA, CL), CHU d'Angers, L'UNAM Université, Angers; Service de Dermatologie et Dermatologie Pédiatrique, Centre de Référence pour les Maladies Rares de la Peau, U1035 (AT), CHU de Bordeaux, Bordeaux; Service d'Hématologie (GS) and Service de Radiologie, CREATIS, UMR5220 CNRS, U1044 Inserm (FC), Hôpital Sud, Service de Pneumologie, Centre de Référence pour les Maladies Pulmonaires Rares (CK), Hospices Civils de Lyon, Université Claude Bernard Lyon I, Lyon; Service d'Onco-Hématologie (HM), Centre Hospitalier de La Roche-Sur-Yon, La Roche-Sur-Yon; Service d'Onco-Hématologie (KG), Centre Hospitalier de Beauvais, Beauvais; Service de Médecine Interne (FA), Hôpital Bicêtre, APHP, Université Paris Sud XI, Le Kremlin-Bicêtre; Service d'Hématologie et Immunologie Pédiatrique (AB), Hôpital Robert Debré, APHP, Université Paris Diderot and Service de Pneumologie A, Centre de Compétence Maladies Pulmonaires Rares (RB), Hôpital Bichat, APHP, Paris; Service de Médecine Interne (CMH), Centre Hospitalier d'Annecy, Annecy; Service de Médecine Interne, Hôpital Foch, Suresne; EA4340, Biomarqueurs en Cancérologie et en Onco-Hématologie, Université Versailles-Saint-Quentin-en-Yvelines (JEK), France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000000088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602413PMC
October 2014

Detection of non-Hodgkin's lymphoma in ovarian cortex pieces during the process of cryopreservation.

J Assist Reprod Genet 2014 Sep 15;31(9):1251-5. Epub 2014 Jul 15.

Service de Gynécologie Endocrinienne et de Médecine de la Reproduction, Hôpital Jeanne de Flandre, CHRU de Lille, 3 avenue Eugène Avinée, 59037, Lille Cedex, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10815-014-0292-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156947PMC
September 2014

Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay.

Fertil Steril 2014 Aug 18;102(2):483-7. Epub 2014 Jun 18.

Laboratoire de Biochimie & Hormonologie, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire, Lille, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00150282140046
Publisher Site
http://dx.doi.org/10.1016/j.fertnstert.2014.05.014DOI Listing
August 2014

A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Clin Cancer Res 2014 Jan 16;20(1):213-20. Epub 2013 Oct 16.

Authors' Affiliations: Institut Gustave Roussy, Villejuif; Centre Hospitalier Universitaire Henri Mondor-Chenevier, Creteil; Centre Henri Becquerel, Rouen; Centre Hospitalier Universitaire de Lille, Lille; Centre Hospitalier Universitaire Pontchaillou, Rennes; Sanofi, Paris; Hospices Civils de Lyon and Université Lyon-1, Lyon, France; and ImmunoGen, Inc., Waltham, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/20/1/213.full.
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-0580DOI Listing
January 2014

Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.

J Clin Oncol 2014 Jan 2;32(3):212-8. Epub 2013 Dec 2.

Tim M. Illidge, Sam Mayes, John A. Radford, W. David J. Ryder, Manchester Academic Health Science Centre, University of Manchester; Jill Tipping, Maureen Zivanovic, Christie Hospital NHS Foundation Trust, Manchester; Ruth Pettengell, St. George's, University of London, London; Andrew T. Bates, Southampton University Hospitals NHS Foundation Trust, Southampton; Mike Bayne, Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; Steven Le Gouill, Centre Hospitalier Universitaire Nantes; Françoise Kraeber-Bodere, Caroline Bodet-Milin, University Hospital-ICO-CRCNA INSERM U892, Nantes; Emmanuel Malek, Damien Huglo, Hospitalier Universitaire Lille; Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Fabrice Jardin, Centre Henri Becquerel, Rouen; Manuel Bardies, Centre de Recherche en Cancérologie de Toulouse, Faculté de Médecine de Toulouse-Rangueil, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.3110DOI Listing
January 2014

[Brentuximab vedotin: new treatment for CD30+ lymphomas].

Bull Cancer 2013 Jul-Aug;100(7-8):775-9

Hôpital Claude-Huriez, CHRU Lille, Service des Maladies du Sang, rue Michel-Polonovski, 59037 Lille cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2013.1778DOI Listing
September 2013

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).

Blood 2013 Aug 10;122(7):1137-43. Epub 2013 Jul 10.

The University of Manchester and Christie National Health Service Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-01-481341DOI Listing
August 2013